

Maria Gavriatopoulou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5384146/publications.pdf>

Version: 2024-02-01

245
papers

6,531
citations

76326

40
h-index

95266

68
g-index

246
all docs

246
docs citations

246
times ranked

7450
citing authors

#	ARTICLE	IF	CITATIONS
1	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.	3.6	30
2	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-51.	1.6	22
3	Utilization and tolerance of beta-blockers among patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 31-37.	3.0	2
4	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.	2.5	18
5	Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. <i>American Journal of Hematology</i> , 2022, 97, 119-128.	4.1	36
6	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 117-118.	3.9	7
7	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. <i>British Journal of Cancer</i> , 2022, 126, 79-90.	6.4	11
8	Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy. <i>American Journal of Hematology</i> , 2022, 97, E27.	4.1	5
9	Nonselective proteasome inhibitors in multiple myeloma and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 335-347.	1.8	4
10	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.	5.2	10
11	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 65-76.	10.7	80
12	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. <i>Biomedicines</i> , 2022, 10, 204.	3.2	7
13	Olive oil intake and cancer risk: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0261649.	2.5	31
14	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.	1.4	28
15	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	3.2	21
16	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.	2.7	17
17	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. <i>Radiology</i> , 2022, 304, 137-144.	7.3	18
18	Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7

#	ARTICLE	IF	CITATIONS
19	Diabetes mellitus and multiple myeloma; common features of two distinct entities. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3535.	4.0	4
20	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3088.	2.4	2
21	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD". <i>Cancers</i> , 2022, 14, 2768.	3.7	6
22	Chromosome 1q21 aberrations identify ultra-high-risk myeloma with prognostic and clinical implications. <i>American Journal of Hematology</i> , 2022, 97, 1142-1149.	4.1	10
23	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 19-23.	3.0	22
24	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 3-11.	3.0	18
25	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021, 21, 167-179.	3.6	232
26	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2021, 193, 113-118.	2.5	15
27	Screening for Gaucher disease among patients with plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 2021, 62, 761-763.	1.3	2
28	COVID-19: time to flatten the infodemic curve. <i>Clinical and Experimental Medicine</i> , 2021, 21, 161-165.	3.6	27
29	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	2.5	11
30	SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2021, 5, e547.	2.7	31
31	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. <i>Leukemia</i> , 2021, 35, 1418-1427.	7.2	15
32	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. <i>Cancers</i> , 2021, 13, 763.	3.7	3
33	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , 2021, 13, 1257.	3.7	9
34	Exercise-Induced Changes in Tumor Growth via Tumor Immunity. <i>Sports</i> , 2021, 9, 46.	1.7	7
35	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021, 9, 546.	3.6	14
36	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. <i>American Journal of Roentgenology</i> , 2021, 216, 742-751.	2.2	8

#	ARTICLE	IF	CITATIONS
37	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	4.4	8
38	Integrin expression in correlation to clinicopathological features and prognosis of prostate cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 221-232.	1.6	3
39	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.0	11
40	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021, 137, 3674-3676.	1.4	130
41	Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1509.	2.4	2
42	Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8019-8019.	1.6	2
43	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.1	16
44	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 361-367.	0.4	10
45	Real-World Treatment of Patients With Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 379-385.	0.4	11
46	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.	3.7	12
47	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. <i>Journal of Infection</i> , 2021, 83, 1-16.	3.3	127
48	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	4.4	25
49	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. <i>HemaSphere</i> , 2021, 5, e614.	2.7	7
50	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	4.1	38
51	ASSOCIATION OF -308G/A, -238G/A TNF- β POLYMORPHISMS WITH MULTIPLE MYELOMA RISK AND SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	2
52	Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 987-995.	2.4	4
53	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. <i>Cancers</i> , 2021, 13, 4047.	3.7	8
54	COVID-19 Vaccines in Patients With Cancer "A Welcome Addition, but There Is Need for Optimization. <i>JAMA Oncology</i> , 2021, 7, 1113.	7.1	19

#	ARTICLE	IF	CITATIONS
55	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.8	3
56	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	6.2	103
57	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	3.7	44
58	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	5.2	39
59	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 259-266.	3.0	8
60	Early and late endocrine complications of COVID-19. <i>Endocrine Connections</i> , 2021, 10, R229-R239.	1.9	32
61	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021, 10, 4179.	2.4	10
62	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	2.6	8
63	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	2.2	15
64	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 26.	3.3	26
65	Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10956.	4.1	8
66	Metabolic Disorders in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11430.	4.1	16
67	Pembrolizumab in endometrial cancer: Where we stand now (Review). <i>Oncology Letters</i> , 2021, 22, 821.	1.8	10
68	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	2.4	25
69	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.	4.4	10
70	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5057.	3.7	6
71	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021, 138, 4202-4202.	1.4	0
72	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3886-3886.	1.4	5

#	ARTICLE	IF	CITATIONS
73	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 2736-2736.	1.4	4
74	Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with <i>MYD88</i> and <i>CXCR4</i> Mutations. <i>Blood</i> , 2021, 138, 1362-1362.	1.4	8
75	Metachronous Bilateral Testicular Plasmacytoma After an Initial Soft Tissue, Extramedullary Plasmacytoma. <i>Cureus</i> , 2021, 13, e19517.	0.5	2
76	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	1.4	6
77	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. <i>Biomedicines</i> , 2021, 9, 1811.	3.2	8
78	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13144.	4.1	13
79	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	7.7	42
80	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 57-62.	0.4	10
81	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 93.	6.2	13
82	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Cancers</i> , 2020, 12, 2864.	3.7	12
83	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3201.	2.4	1
84	<p>Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6405-6416.	2.0	12
85	Cholangiocarcinoma: investigations into pathway-targeted therapies. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 765-773.	2.4	13
86	Organ-specific manifestations of COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020, 20, 493-506.	3.6	351
87	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	1.6	102
88	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. <i>Leukemia and Lymphoma</i> , 2020, 61, 3247-3250.	1.3	3
89	Response of an oncology unit in the midst of the COVID-19 outbreak. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1947-1952.	0.9	1
90	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 109.	6.2	21

#	ARTICLE	IF	CITATIONS
91	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3245.	3.7	24
92	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1563-1573.	13.7	188
93	Multiple myeloma: Current and future management in the aging population. <i>Maturitas</i> , 2020, 138, 8-13.	2.4	7
94	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.	1.8	9
95	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2246-2249.	1.3	0
96	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 860.	2.8	35
97	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	1.3	46
98	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 25.	6.2	16
99	The current role of BTK inhibitors in the treatment of Waldenström's Macroglobulinemia. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 663-674.	2.4	4
100	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020, 4, e381.	2.7	14
101	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020, 95, 465-471.	4.1	9
102	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e905-e909.	0.4	9
103	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.2	54
104	Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. <i>Cancers</i> , 2020, 12, 191.	3.7	48
105	Antibody therapies for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 295-303.	3.1	7
106	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 103-110.	3.0	11
107	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.4	23
108	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020, 95, E148-E150.	4.1	12

#	ARTICLE	IF	CITATIONS
109	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.8	31
110	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	1.8	17
111	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	6.2	15
112	Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing. <i>Blood</i> , 2020, 136, 10-11.	1.4	4
113	Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8501-8501.	1.6	21
114	Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients (Review). <i>Oncology Letters</i> , 2020, 20, 441-447.	1.8	115
115	Clinical biomarkers directing the management of patients with colon and lung cancer (beyond) Tj ETQq1 1 0.784314,rgBT /Oyerlock 10 0,2		
116	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020, 136, 12-12.	1.4	0
117	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020, 136, 8-8.	1.4	0
118	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. <i>Blood</i> , 2020, 136, 48-49.	1.4	7
119	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 25-25.	1.4	1
120	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. <i>Blood</i> , 2020, 136, 19-20.	1.4	0
121	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.	1.4	0
122	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. <i>Blood</i> , 2020, 136, 33-33.	1.4	1
123	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. <i>Blood</i> , 2020, 136, 48-50.	1.4	0
124	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. <i>Blood</i> , 2020, 136, 21-21.	1.4	4
125	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
126	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. <i>Blood</i> , 2020, 136, 28-28.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Current Approaches in the Management of Hepatic Adenomas. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 199-209.	1.7	21
128	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019, 125, 744-758.	4.5	22
129	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	27.0	460
130	<p>Evaluating ibrutinib in the treatment of symptomatic Waldenstromâ€™s macroglobulinemia</p>. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 291-300.	1.7	13
131	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 921-928.	2.4	8
132	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.	7.2	53
133	Progression Risk Stratification of Asymptomatic WaldenstrÃ¶m Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	1.6	65
134	Multiple Myeloma Bone Disease. , 2019, , 329-340.		0
135	Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop. <i>Scientific Reports</i> , 2019, 9, 3245.	3.3	25
136	Meat, fish, dairy products and risk of hematological malignancies in adults â€“ a systematic review and meta-analysis of prospective studies. <i>Leukemia and Lymphoma</i> , 2019, 60, 1978-1990.	1.3	15
137	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	1.8	9
138	Updates on thrombotic events associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 355-365.	2.2	11
139	Disappearing liver metastases: A systematic review of the current evidence. <i>Surgical Oncology</i> , 2019, 29, 7-13.	1.6	30
140	Anti-BCMA antibodies in the future management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 319-326.	2.4	19
141	Bone marrow biopsy in lowâ€“risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.	4.1	11
142	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	2.7	20
143	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.2	17
144	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	5.2	37

#	ARTICLE	IF	CITATIONS
145	Treatment of Bingâ€œNeel syndrome with first line sequential chemoimmunotherapy. <i>Medicine (United Tj ETQq1</i> 1,0784314rgBT /Ove	1.0	14
146	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 23-28.	0.4	2
147	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	4.1	21
148	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	5.1	10
149	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	1.3	9
150	The Role of TAMIS (Transanal Minimally Invasive Surgery) in the Management of Advanced Rectal Cancer â€œ One Shared Story of Three Exceptional Cases. <i>Journal of Investigative Surgery</i> , 2019, 32, 371-376.	1.3	1
151	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 5528-5528.	1.4	1
152	The extended 4-year follow-up results of the ELOQUENT-2 trial. <i>Oncotarget</i> , 2019, 10, 82-83.	1.8	10
153	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2019, 134, 1877-1877.	1.4	0
154	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2019, 134, 1842-1842.	1.4	0
155	Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 1894-1894.	1.4	1
156	Biology and treatment of myeloma related bone disease. <i>Metabolism: Clinical and Experimental</i> , 2018, 80, 80-90.	3.4	49
157	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.	1.4	44
158	Clear cell â€œsugar tumorâ€œ of the lung: Diagnostic features of a rare pulmonary tumor. <i>Respiratory Medicine Case Reports</i> , 2018, 23, 52-54.	0.4	9
159	Pathogenesis of bone disease in multiple myeloma: from bench to bedside. <i>Blood Cancer Journal</i> , 2018, 8, 7.	6.2	219
160	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With WaldenstrÃ¶m Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 431-437.	0.4	5
161	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, 31.	6.2	35
162	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 2002-2004.	1.3	6

#	ARTICLE	IF	CITATIONS
163	The role of ibrutinib in Waldenström macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 85-89.	0.8	0
164	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	1.4	54
165	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq1 1 0.784314 rgBT /Ove 2018, 59, 983-987.	1.3	4
166	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	3.0	24
167	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. <i>Blood Cancer Journal</i> . 2018, 8, 102.	6.2	23
168	Micronutrient Intake and Risk of Hematological Malignancies in Adults: A Systematic Review and Meta-analysis of Cohort Studies. <i>Nutrition and Cancer</i> , 2018, 70, 821-839.	2.0	12
169	Management of multiple myeloma bone disease: impact of treatment on renal function. <i>Expert Review of Hematology</i> , 2018, 11, 881-888.	2.2	10
170	Optimizing therapy in bortezomib-exposed patients with multiple myeloma. <i>Expert Review of Hematology</i> , 2018, 11, 463-469.	2.2	1
171	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 46.	6.2	39
172	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	7.2	81
173	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	7.2	40
174	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 42.	6.2	29
175	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. <i>Blood</i> , 2018, 132, 1966-1966.	1.4	3
176	How I treat elderly patients with plasma cell dyscrasias. <i>Aging</i> , 2018, 10, 4248-4268.	3.1	9
177	How I treat rituximab refractory patients with WM. <i>Oncotarget</i> , 2018, 9, 36824-36825.	1.8	6
178	Ibrutinib for rituximab-refractory Waldenström macro-globulinemia. <i>Oncotarget</i> , 2018, 9, 12536-12537.	1.8	1
179	Optimising Treatment in Relapsed, Refractory Multiple Myeloma. <i>European Oncology and Haematology</i> , 2018, 14, 96.	0.0	0
180	IMiDs for myeloma induced renal impairment. <i>Oncotarget</i> , 2018, 9, 35476-35477.	1.8	4

#	ARTICLE	IF	CITATIONS
181	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018, 132, 3247-3247.	1.4	0
182	Emerging treatment approaches for myeloma-related bone disease. <i>Expert Review of Hematology</i> , 2017, 10, 217-228.	2.2	13
183	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1-9.	2.4	4
184	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2304-2309.	1.3	17
185	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.	4.1	48
186	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017, 102, 593-599.	3.5	72
187	Current treatment options and investigational drugs for Waldenström's Macroglobulinemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 197-205.	4.1	12
188	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017, 58, 1832-1839.	1.3	24
189	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. <i>Blood</i> , 2017, 129, 456-459.	1.4	62
190	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 1707-1714.	1.8	7
191	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1506-1508.	1.3	9
192	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017, 1, 449-454.	5.2	89
193	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016, 91, 499-502.	4.1	73
194	Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. <i>Blood</i> , 2016, 128, 405-409.	1.4	37
195	<i>TLR4/TIRAP</i> polymorphisms are associated with progression and survival of patients with symptomatic myeloma. <i>British Journal of Haematology</i> , 2016, 172, 44-47.	2.5	8
196	Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2165-2177.	1.8	28
197	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1776-1780.	1.3	3
198	Neutrophil Gelatinase-Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 29-35.	0.4	16

#	ARTICLE	IF	CITATIONS
199	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	1.4	37
200	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. <i>Blood</i> , 2016, 128, 4500-4500.	1.4	0
201	Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. <i>American Journal of Hematology</i> , 2015, 90, E60-5.	4.1	55
202	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. <i>Haematologica</i> , 2015, 100, e446-e449.	3.5	44
203	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015, 126, 1392-1394.	1.4	108
204	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. <i>Annals of Hematology</i> , 2015, 94, 2033-2042.	1.8	43
205	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2018-2023.	1.3	57
206	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014, 89, 34-40.	4.1	33
207	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. <i>Blood</i> , 2014, 124, 306-306.	1.4	4
208	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. <i>Blood</i> , 2014, 124, 4738-4738.	1.4	3
209	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014, 124, 4769-4769.	1.4	1
210	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. <i>Blood</i> , 2014, 124, 2028-2028.	1.4	0
211	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2014, 124, 2029-2029.	1.4	0
212	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3462-3462.	1.4	0
213	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. <i>Blood</i> , 2014, 124, 3464-3464.	1.4	0
214	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. <i>Blood</i> , 2014, 124, 2130-2130.	1.4	0
215	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. <i>Blood</i> , 2014, 124, 2115-2115.	1.4	0
216	Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. <i>Blood</i> , 2014, 124, 5741-5741.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i> , 2013, 122, 3276-3282.	1.4	180
218	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. <i>Hematological Oncology</i> , 2013, 31, 96-102.	1.7	55
219	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. <i>American Journal of Hematology</i> , 2013, 88, 765-770.	4.1	40
220	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenström's Macroglobulinemia. <i>Blood</i> , 2013, 122, 1860-1860.	1.4	2
221	The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). <i>Blood</i> , 2013, 122, 3196-3196.	1.4	1
222	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. <i>Blood</i> , 2012, 119, 5384-5390.	1.4	88
223	Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. <i>American Journal of Hematology</i> , 2012, 87, 734-736.	4.1	8
224	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. <i>American Journal of Hematology</i> , 2012, 87, 861-864.	4.1	81
225	Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease. <i>Blood</i> , 2012, 120, 1819-1819.	1.4	7
226	Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 115-117.	0.4	10
227	Prognostication of the High-Risk WM Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 127-129.	0.4	1
228	Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. <i>European Journal of Haematology</i> , 2011, 87, 323-329.	2.2	8
229	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. <i>American Journal of Hematology</i> , 2011, 86, 479-483.	4.1	43
230	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884.	4.1	16
231	Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. <i>European Journal of Haematology</i> , 2010, 85, 1-5.	2.2	28
232	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem cell transplantation: Results of a single institution, randomized phase 2 trial. <i>American Journal of Hematology</i> , 2010, 85, 863-867.	4.1	44
233	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. <i>Leukemia Research</i> , 2010, 34, 399-402.	0.8	26
234	Validation of the International Prognostic Scoring System (IPSS) for Waldenström's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010, 34, 1340-1343.	0.8	56

#	ARTICLE	IF	CITATIONS
235	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. <i>Leukemia Research</i> , 2010, 34, 1395-1397.	0.8	64
236	High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. <i>British Journal of Haematology</i> , 2010, 150, 587-591.	2.5	11
237	Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.	0.4	20
238	Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. <i>Blood</i> , 2010, 116, 2963-2963.	1.4	7
239	Applications of monoclonal antibodies for the treatment of hematological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 207-220.	3.1	15
240	Angiogenesis in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 46-49.	1.4	12
241	Rituximab-Based Treatments in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 59-61.	1.4	12
242	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 302-306.	1.4	101
243	Dickkopf-1: a suitable target for the management of myeloma bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 839-848.	3.4	62
244	Treatment of light chain deposition disease with bortezomib and dexamethasone. <i>Haematologica</i> , 2009, 94, 300-302.	3.5	70
245	Antibody Therapies for Multiple Myeloma. , 0, , .		0